HC Wainwright Begins Coverage on Inventiva (NASDAQ:IVA)

HC Wainwright began coverage on shares of Inventiva (NASDAQ:IVA) in a research report released on Wednesday morning, MarketBeat reports. The firm issued a buy rating and a $20.00 target price on the stock. HC Wainwright also issued estimates for Inventiva’s FY2025 earnings at ($1.44) EPS, FY2026 earnings at ($1.66) EPS, FY2027 earnings at ($2.43) EPS, FY2028 earnings at $0.49 EPS and FY2029 earnings at $3.19 EPS.

Several other research analysts also recently commented on the company. Piper Sandler started coverage on Inventiva in a report on Wednesday, August 27th. They issued an “overweight” rating and a $26.00 price objective on the stock. Guggenheim lifted their price objective on Inventiva from $9.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Inventiva has a consensus rating of “Moderate Buy” and a consensus price target of $14.83.

Inventiva Trading Down 0.5%

IVA opened at $5.57 on Wednesday. The business’s 50-day moving average price is $3.90 and its 200-day moving average price is $3.46. Inventiva has a 12 month low of $1.53 and a 12 month high of $6.50.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Inventiva stock. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) by 54.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,558 shares of the company’s stock after purchasing an additional 5,843 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Inventiva were worth $50,000 at the end of the most recent reporting period. 19.06% of the stock is owned by institutional investors and hedge funds.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.